Amgen Exec Says Co Continues to Be "Laser Focused" on a Phase Three Development Program for Its Obesity Drug Maritide - UBS Healthcare Conference
安進高管表示公司繼續"銳意專注"於其肥胖藥物馬利替德的三期開發計劃-UBS醫療保健會議
Amgen Exec Says Co Continues to Be "Laser Focused" on a Phase Three Development Program for Its Obesity Drug Maritide - UBS Healthcare Conference
安進高管表示公司繼續"銳意專注"於其肥胖藥物馬利替德的三期開發計劃-UBS醫療保健會議
譯文內容由第三人軟體翻譯。